Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ready to load more PharmaCyte!!!
....need more!
Maybe we’ll get those sweet “SUB PENNY” prices April 15, 2050
Aaaahahahahahahaha!!!!!!!!
IND submission underway!
Patience :)
Sir GENIUS KW rocks!!!
Go Team PharmaCyte!!!!!
ATTENTION!!!!!
AMERICAN COMPANY PHARMACYTE BIOTECH "IND submission" news is imminent!!!
"PHARMACYTE'S MOMENTUM OF SUCCESS CAN'T BE STOPPED!!!"
TRUTH and FACTS HERE: https://pharmacyte.com/
Patience.
BUY AMERICAN!!! :)
Sir GENIUS KW rocks!!!
Go Team PharmaCyte!!!
lol
Hope you guys are staying healthy :)
Continue with patience.
Submission progressing slowly but surely.
Go Team PharmaCyte!!!
Would you put a NEW CAR on your lot WITHOUT PAPERS AND A WARRANTY?
Hmmm...My quoted sentence is NOT complete.
Ready to back the truck up and LOAD!!!!
Is it gonna drop?
(((((SUB PENNY???)))))
Maybe...maybe NOT!!!!!
((((((ROLMAO!!!!!!)))))
KW rocks!!!
NOTHING THERE PROVING PHARMACYTE TO BE A SCAM!!!!! Other than normal biotech startup operational practices, THERE IS “NO” ILLEGAL WRONGDOINGS THE CEO AND/OR PHARMACYTES TEAM OF WORLD RENOWNED DOCTORS AND SCIENTISTS ARE DOING!!!!!! THERE IS (((ABSOLUTELY NOTHING))) SHOWING AND PROVING WHY THIS COMPANY IS NOT A LEGITIMATE COMPANY!!!! THOSE LINKS PROVIDED SHOW NOTHING OF THE KIND!!!! BTW SIR GENIUS KW ROCKS!!!
PHARMACYTE ROCKS!!!
Show us proof bearspread!!!....PLEASE, ANY LINK TO YOUR EVIDENCE OF THIS BEING A SCAM???
Yeah, because LÖHR VONHOFF and GÜNZBURG are known to record their “SCAM WORK” from PharmaCyte’s PC development in public for the world to see!
((((((((ROLMAO!!!!!!!!)))))))
Sure pp....those WORLD RENOWNED DOCTORS are actually scam artists!!!!!!
Aaahahahahaha!!!!!!!
Aaahahahahaha!!!!!!!!!!!!
Interesting research from PharmaCyte’s PI Hidalgo and Pfizer....
https://news.weill.cornell.edu/news/2020/02/targeted-drug-may-improve-chemotherapy-effectiveness-in-pancreatic-cancer
Meanwhile....
“Sir GENIUS KW” obliterates the “dreamy dream of PharmaCyte’s MYTHICAL FAILURE !!!!!!!!
BIGLY!!! ((((ROLMAO!!!))))
”DESTROYED IT!!!!!!!!!!!”
Aaaahahahahaha!!!!!!!!!!!!
Dr. Manuel Hidalgo is PI
of ”UPCOMING TRIALS”
Manuel Hidalgo FACTS:
• Internationally-renowned oncologist and clinical investigator in pancreas and other cancers
• Co-founder and Chairman of the International Pancreatic Cancer Research Team
• Assisted in the development of more than 30 novel oncology drugs; several for pancreas cancer
• Head of Clinical Development at the Spanish National Cancer Research Center in Madrid and Co-Director of
Drug Development and Gastrointestinal Oncology at Johns Hopkins University
• Currently Clinical Director of the Rosenberg Clinical Cancer Center and Chief of the Division of HematologyOncology at Beth Israel Deaconess Medical Center in Boston
PharmaCyte SUCCESSFULLY COMPLETES
CiaB Pancreatic Cancer Targeting Therapy
https://pharmacyte.com/pharmacyte-biotech-receives-certificates-of-analysis-and-batch-records-for-its-clinical-trial-product-in-pancreatic-cancer/
IND submission ABSOLUTELY underway!!!
Slowly but Surely!
GENIUS CEO “KW” rocks!!!
Go Team PharmaCyte!!!
You’re sooooo spot on!!!
((((((((ROLMAO!!!!!!))))))))
I'm here all day SB LOL!!!!!!!!!!!!!!!!!
PharmaCyte...AWESOME TECHNOLOGY!!!
“MAYBE” the FDA really did require something extra.... I honestly don’t know.
Also, I get your frustration...but KW doesn’t need any help...since the beginning he’s been doing what it takes to get the job done.
And what you want, apparently ain’t gonna happen...ain’t gotta happen either.
EVERY...SINGLE...TIME...prior to each successful milestone they’ve achieved, it’s been the same old, same old from two different groups here...
The ones with no patience, and the ones who just can’t get enough of KW annihilating the dreamy dream of PharmaCyte’s failure.
...just not gonna happen in my view...at least not with the TEAM we have in place.
That’s FACT!
That’s it...end of story.
Best remedy? ....patience.
Hate to say it, but after 20+ ...we really are there.
Relax...it’ll happen.
And if it don’t....I’d be the first to say it was a fun bet.
...think how the milestones CONTINUE to roll...one after another.
Yeah!... :)
LOL!!!....we are there!!!
Aahahahahahaha!!!!!!!
....just give it a little more time!
Hey, no one knew this pandemic bullchet was gonna happen!
Just gotta have patience man!!!!!!
PharmaCyte is like a pure bred BLUETICK!!!
PharmaCyte continues to ROCK!!!!
MILESTONE after MILESTONE!!!!
Sir GENIUS KW and PharmaCyte Biotech is KING of CELLULOSE BASED CELL ENCAPSULATION!!!
(cue the royal trumpets)
Aaaahahahahahahaha!!!!!!!!!!!
AGAIN...this is the OFFICIAL and LEGITIMATE company website where you’ve always been able to get the FACTS and LINKS that’s ALWAYS provided you with the same answers you request REPEATEDLY.
https://pharmacyte.com/
Answers like this one for example that was previously posted...
*****The primary tumor did not grow in any of the 14 patients.
Two patients had a PR, 12 patients exhibited SD, and two patients showed an MR.
(“SD”; tumors 50-125% of initial size), partial remission (“PR”; more than 50% reduction in tumor volume) an[color=red][/color]d minor response (“MR”; tumor reduction of between 25% and 50%).
Imagine what improved cells, more cells in the caps and multiple doses can now achieve? . These results were measured by 20 year old catscan. Imagine what the new imaging technology will be able to see.
The two Phase 1/2 clinical trials referred to above were carried out in Europe in the late 1990s-early 2000s that employed the combination of the cellulose-based live cell encapsulation technology, now known as Cell-in-a-Box®, with the anticancer drug ifosfamide. The results of the first of the two studies have appeared in the peer-reviewed scientific literature, but the report of the second has yet to appear in the public domain; accordingly, the discussion below relates to the single trial which has appeared in the scientific literature.
Dates of Trial and Location
The trial was opened on July 28, 1998 and closed on September 20, 1999. The trial was carried out at the Division of Gastroenterology, University of Rostock, Germany.
Identity of Trial Sponsors
The trial was sponsored by Bavarian Nordic GmbH.
Trial Design
The trial was an open-label, prospective, single-arm and single center study.
Patient Information
A total of 17 patients were enrolled in the trial (51 were screened). A total of 14 patients were treated because two of the original 17 patients developed severe infections before the start of the trial and had to be treated by other means and angiography was not successful in a third patient.
Criteria for entering the study the study included: inoperable pancreatic adenocarcinoma stage III-IV (IUCC) as determined by histology and measured by CAT scan and with no prior chemotherapy.
Duration of Treatment and Dosage Information
On day 0, celiac angiography was performed and 300 (in 13 patients, 250 in one) of the capsules containing the ifosfamide-activating cells were placed by supraselective catheterization of an artery leading to the tumor. Each capsule (~0.8 mm in diameter) contained about 10,000 cells. The cells overexpressed an enzyme, CYP2B1 (a variant of the cytochrome P450 system), which catalyzed the conversion of the anticancer drug ifosfamide (Holoxan®, Ifex®) into its “cancer-killing” form.
On day 1, patients were monitored for evidence of any clinically relevant adverse reactions, e.g. allergy and/or pancreatitis.
On days 2-4, each patient received low-dose (1 g/m2 body surface area) ifosfamide in 250 ml of normal saline was administered systemically as a 1-hour infusion. This was accompanied by a 60% dose equivalent of the uroprotector MESNA given as three intravenous injections. This regimen was repeated on days 23-25 for all but two patients who received only one round of ifosfamide. A total of two treatments with ifosfamide were given.
Specific Clinical Endpoints
Median survival time from the time of diagnosis, the percentage of patients who survived one year of more, and quality of life were examined in the trial.
Observational Metrics Utilized and Actual Results Observed
Standard NCI criteria for evaluating tumor growth were used to assess stable disease (“SD”; tumors 50-125% of initial size), partial remission (“PR”; more than 50% reduction in tumor volume) and minor response (“MR”; tumor reduction of between 25% and 50%).
Effects of the treatment on tumor size were measured by CAT scans. Control CAT scans were scheduled for weeks 10 and 20, respectively. During the final visit, a control angiography was performed. On the initial CAT scan, the scan demonstrating the largest diameter of the primary tumor was identified and the area measured. Using appropriate landmarks, an identical scan was used for comparison. CAT scans were evaluated by two unrelated radiologists, one of whom was not involved in the study. After formally finishing the study, patients were followed on an ambulatory basis with three-monthly visits.
Toxicity was measured based on WHO/NCI guidelines on common toxicity criteria.
The need for pain medication and quality of life (“QOL”) was monitored using a questionnaire established for pancreatic diseases. A QOL questionnaire for cancer patients, QLQ-C30, had been validated in several languages, but the module for pancreatic cancer per se was still under development at the time of the study with respect to reliability, sensibility against changes, and multicultural validation. Accordingly, an unauthorized version of the core questionnaire and a German QOL scale (published in 1995) for pancreas disease patients was used. QOL data were documented independently from safety and efficacy data by having patients complete an independent questionnaire. Assessment of QOL data did not interfere with routine documentation of adverse events reported by the patients. QOL questionnaires were analyzed according to EORTC criteria. QOL data were available from the baseline evaluation for 14 patients and for analysis of change for 8 patients.
A clinical benefit score based on variable including Karnofsky score, body weight, pain and analgesic consumption was calculated from the QOL questionnaires. Pain intensity was measured on a visual analog scale ranging from 0 (no pain) to 100 (the most intensive pain imaginable), in increments of 10. Analgesic consumption was assessed using a separate scale in which 0 indicated no regular consumption of analgesic, and 25, 50, and 100 indicated administration of non-steroidal anti-inflammatory drugs or opiates several times per year, per month or per week, respectively.
The primary tumor did not grow in any of the 14 patients. Two patients had a PR, 12 patients exhibited SD, and two patients showed an MR.
Median survival time of patients in this trial was 39 weeks. The one-year survival rate was 36%.
Within the 20-week study period, three patients died from disease progression (on days 9, 85, and 132). Upon postmortem examination, the patient who died on day 9 (from recurrent pulmonary embolism) was found to have extensive tumor (well differentiated adenocarcinoma) necrosis.
The chemotherapy regimen was well tolerated with no toxicity beyond Grade II being detected in any of the 14 patients; thus, there was no obvious specific treatment-related risk.
Eleven serious adverse events (“SAEs”) were seen in 7 patients during the study period; none were treatment-related (i.e. due to capsule implantation or ifosfamide administration). These SAEs were attributed to underlying disease and/or the effects associated with the disease.
Administration of the capsules did not result in any obvious allergic or inflammatory response and no patients developed pancreatitis during the study. Some patients exhibited elevated amylase levels, presumably due to tumor infiltration of the pancreas and limited obstructive chronic pancreatitis, but no further increase in amylase levels was seen after angiography and capsule placement.
Only one adverse event (increased lipase activity on day 15 after installation of the capsules) may have been linked to capsule administration.
If a “clinical benefit” is considered to be either no increase or a decrease in pain intensity, then 10 of 14 experienced such a benefit. For 7 of the patients, this was confirmed by their analgesic consumption. None of these “benefited” patients registered an increase analgesic usage both in terms of dosage or WHO level.
None of the patients showed an increased Karnofsky index after treatment. However, 7 of the 14 patients had stable Karnofsky indices at the week 10 assessment and for 4 of those, their indices were still stable at week 20.
One patient’s body weight increased at both weeks 10 and 20 and another patient showed increased weight at week 10 (this patient withdrew from the study and no week 20 weight was obtained. Two patients showed stable body weights at week 10, one of whom dropped out of the study and the other showed weight loss at week 20.
Two scenarios were used to establish the overall integrative clinical benefit response, where each patient was given a +2 score for an improved value, a +1 score for a stable value, and a -1 score for a worsened value for each of the four criteria (pain, analgesic consumption, Karnofsky index, and body weight) as compared to the relevant week 0 values.
Mr. Jeffrey P. Riedler
Assistant Director
Securities and Exchange Commission
Page 10
The “worst case scenario” required a pain relief score of 20 points or more to be judged an improvement and a decrease in the Karnofsky index of 10 points or more to indicate worsening. Using this scenario, 50% (7) of the treated patients experienced clinical benefit, 21.4% (3) patients were neutral (benefits were offset by impairments) and 28.6% (4) patients (had no clinical benefit; the latter included those dying before the median survival time.
In the “best case scenario,” a pain relief score of 10 points or more was an improvement, and a decrease in Karnofsky index of 20 pints or more is considered a worsening. In this scenario, 71.4% (10) of patients had clinical benefit, 14.2% of patients showed neither benefit nor deterioration, and 14.3% patients definitely had no benefit.
Comparisons to Standard of Care
At the time that the clinical trial was conducted, only one FDA-approved treatment for advanced, inoperable pancreatic cancer was available; that was Gemzar® (gemcitabine), an Eli Lilly drug first approved by the FDA in 1996.
An examination of the prescribing information for Gemzar® reveals that the median survival seen in the pancreatic cancer clinical trial for that drug was approximately 23 weeks (5.7 months) an the percentage of one-year survivors was approximately 18%. By comparison, corresponding values revealed in the Phase 1/2 trial of the CapCell® plus ifosfamide combination were 39 weeks (~9.8 months) and 36%, respectively.
The treatment with Gemzar® of patients with pancreatic cancer is often associated with severe side effects. According to the prescribing information for Gemzar®, for use against pancreatic cancer, the recommended dose of Gemzar® is 1000 mg/m2 given intravenously over 30 minutes. The schedule of administration is: weeks 1-8, weekly dosing for 7 weeks followed by one week rest and then after week 8, weekly dosing on days 1, 8 and 15 of 28-day cycles.
Dose reductions of Gemzar® are necessitated by the occurrence of myelosuppression and permanent discontinuation of administration of Gemzar® is necessary for any of the following:
· Unexplained dyspnea or other evidence of severe pulmonary toxicity
· Severe hepatotoxicity
· Hemolytic-uremic syndrome
· Capillary leak syndrome
· Posterior reversible encephalopathy syndrome
Gemzar® should be withheld or its dose reduced by 50% for other severe (Grade 3 or 4) non-hematologic toxicity until that toxicity is resolved. No dose reductions of Gemzar® are recommended for alopecia, nausea or vomiting.
In contrast to the SAE’s seen with Gemzar® administration, as noted above (see Observational Metrics Utilized and Actual Results Observed), the use of the CapCell® plus ifosfamide combination in this Phase 1/2 trial was not associated with any serious (Grade 3 or 4) treatment-related side effects.
Mr. Jeffrey P. Riedler
Assistant Director
Securities and Exchange Commission
Page 11
Conclusions Drawn, Etc.
The CapCell® plus ifosfamide combination as used in this Phase 1/2 trial was both safe and efficacious for the treatment of advanced, inoperable pancreatic cancer. In fact, the efficacy of this combination as shown in this Phase I/II trial appears to exceed that of the current best available chemotherapeutic treatment for advanced, inoperable pancreatic cancer, namely the combination of Abraxane® plus gemcitabine, for this disease.
Because only 14 patients were treated in this Phase 1/2 trial, no statistical parameters were used in determining either safety or efficacy of the CapCell® plus ifosfamide combination in this trial.”
Patents, Intellectual Property and Trade Secrets, page 9
3. We note your statement that “Nuvilex and its subsidiaries...own, co-own or have exclusive worldwide licensing rights to numerous patents in multiple countries over four technical areas: live cell encapsulation, pigment modification, microencapsulation and disinfectant/germicidal compositions.” For each of these technical areas, please expand your disclosure to provide your material patents and any pending patent applications to the extent you have not already done so, including the following:
· A list of specific products, product groups and technologies to which such patents relate;
· Whether such patents are owned or licensed from third parties;
· Type of patent protection such as composition of matter, use or process;
· Patent expiration dates;
· Identification of all applicable jurisdictions, including non-U.S.; and
· Contested proceedings and/or third-party claims
Patience :)
Would I venture to say a slow rolling 2 to 3 months before any kind of significant news?
...in this environment?
Yep!
Chet happens!
You know, like the EPIC FAILURE of the DUMP ILLUSION campaign.
((((((ROLMAO!!!!!!!!))))))
CiaB PC Targeting Therapy STILL STRONG!!!!!
”DUMP ILLUSION” campaign EPIC FAILURE!!!!!
Market worst ever since depression and still hanging .03 !!!!!
Down only one penny since coronavirus killed the market.
(((((((ROLMAO!!!!!!)))))))
LOL!!!...patience. :)
GO TEAM PHARMACYTE!!!!!
LOL!!!...Thank you sir!!!
PLEASE!!!..Does anyone know what happened to the “MYTHICAL FAILURE” of PharmaCyte Biotech and our phenominal Sir GENIUS KW?
...or the “MYTHICAL FAILURE” of our MCB?
...or the “MYTHICAL FAILURE” of our manufacturing of CT product?
...or the “MYTHICAL FAILURE” of our CT product testing?
(((((ROLMAO!!!)))))
NEWS FLASH!!!!:
"THERE WERE NO FAILURES!!!!!!!!!!”
LOL!!! LOL!!! LOL!!! LOL!!! LOL!!!
They were ALL SUCCESSFUL!!!
All the FACTS and TRUTHS
are right here people:
https://pharmacyte.com/
End Results here:
https://pharmacyte.com/pharmacyte-biotech-successfully-completes-all-release-tests-on-clinical-trial-product/
And here:
https://pharmacyte.com/pharmacyte-biotech-receives-certificates-of-analysis-and-batch-records-for-its-clinical-trial-product-in-pancreatic-cancer/
IND submission absolutely UNDERWAY!!! ....slowly, but surely. :)
Patience.
GENIUS KW ROCKED IT!!!!
GO TEAM PHARMACYTE!!!!!!
20+ years of FACTS and TRUTH of PharmaCyte and their recent SUCCESSFUL Cell-in-a-Box PC Targeting Therapy Development can be found right here:
https://pharmacyte.com/
NO SPINS...NO LIES...ONLY TRUTH!!!!!!
Read the FACTS about PharmaCyte from experts like Gunzburg, Salmons, Sher, Makowka, Lohr, Yuen, Hidalgo, Von Hoff, Crabtree, and Medscape!!!!!
,
PHARMACYTE IS NOW KING OF CELLULOSE BASED LIVE CELL ENCAPSULATION!!!!!
IND submission ABSOLUTELY underway!!!!
Patience.
Go Team PharmaCyte!!!!
Still, FANTASTIC NEWS!!!!...
https://pharmacyte.com/pharmacyte-biotech-receives-certificates-of-analysis-and-batch-records-for-its-clinical-trial-product-in-pancreatic-cancer/
Facet slowly but surely continuing to make progress with...
...wait for it...
THE IND SUBMISSION!!!!
BAAAMMMMMMMMMMMMMMM!!!!!!!
Aaaahahahahahaha!!!!!!!!
AN AMAZING PC TARGETING THERAPY SUCCESSFULLY COMPLETED!!!
....PERFECTED!!!!!
Awesome job of Sir GENIUS KW and our PHENOMENAL TEAM!!!
Facet “NOW” processing IND submission!
https://pharmacyte.com/pharmacyte-biotech-receives-certificates-of-analysis-and-batch-records-for-its-clinical-trial-product-in-pancreatic-cancer/
.001 pps?
NOT HAPPENING!!!!!!
(((((ROLMBFAO!!!!!))))
KW is a “STRATEGY GENIUS”
LOL!!!LOL!!!LOL!!!LOL!!!
Stay tuned!!!
Patience :)
KW rocks!!!
Go Team PharmaCyte!!!
Probably right.
Now Sir GENIUS KW can finally get that WELL DESERVED RAISE!!!!!!!
((((((ROLMAO!!!!!!!!)))))
Heeheeheehee!!!!!
VonHoff did his job!!!!!! ..... and it was an OUTSTANDING ONE I might add.
Sir GENIUS KW asked him to join Hildago in designing the clinical trial, and he did...quite successfully!!!!
Did you hear cGMP ever complain about it? NO!!!!!
REMEMBER!, the pyro testing is all we lack....it’s all we’re waiting for.
N O T H I N G HAS (((EVER))) BEEN SAID ABOUT VONHOFF SCREWING UP OUR CLINICAL TRIAL DESIGN!!!!!
THANK YOU!!!!!
RC...Volume check, please, sir!
Waaaaay too much money for me to count!
(((((((ROLMAO!!!!!!!!!!)))))
Yeah...the “value”.
Hey, speaking of, do you suppose the .001 price you mentioned will ever come???
Aaaahahahahahahaha!!!!!!!!!!!!
Hello friend...actually, that’s not so.
In fact, here’s just one of the MANY ACCOMPLISHMENTS of PharmaCyte Biotech.
Sir “GENIUS” CEO KENNETH WAGGONER.
But of course, in giving him all the respect he deserves (including a raise) you can just call him Mr. Waggoner.
(((((ROLMAO!!!!!!!)))))
Aaaahahahahahahaha!!!!!!!!!
Wait a minute!....scratch that plan.
I can’t buy any shares because someone said PharmaCyte was going bankrupt!!!!!
WTF!!!!!!!!
That’s right!... someone said it just the other day.
... and I think last week!!!
... and I think last month!!!
... I think I even heard it being said iall last year!!...and the year before that!...and the year before that!!!
Ha ha Ha Ha Ha Ha Ha!!!!!!
Aahahaha!!!!
Ha Ha Ha Ha Ha!!!!!!!
I feel that (((SUB PENNY))) coming today people!!!
Gonna load the truck up!!!
She’s (((FALLING FAST)))!!!!
H O L Y C H E T!!!!!!!!!!
Aaaahahahahahahaha!!!!!
Aaahahahahaha!!!!
Aaaahahahahahahaha!!!!!